At Centrum Pharmacy, we’re committed to bringing you the latest in medical innovation—and one of the most exciting frontiers today is the potential link between weight-loss medications and cancer prevention.
A new study analyzing 170,000 patient records has revealed that U.S. adults with diabetes who were treated with GLP-1 medications—like Wegovy®, Ozempic®, and Zepbound®—had a slightly lower risk of developing obesity-related cancers compared to those on older diabetes medications not linked to weight loss.
Key Findings:
- A 7% reduction in obesity-related cancer risk
- An 8% lower risk of death from any cause over four years
- The benefit was especially noticeable in women
These GLP-1 receptor agonists not only help regulate blood sugar but also support weight loss by mimicking gut and brain hormones, helping users feel fuller for longer. While these results don’t prove a direct cause-and-effect relationship, they are a promising call to action for further research—and a potential new path in cancer prevention through weight management.
“This is a call to scientists and clinical investigators to do more work in this area to really prove or disprove this,” said Dr. Ernest Hawk of MD Anderson Cancer Center.
At Centrum Pharmacy, our pharmacists are here to support your journey with expert guidance on GLP-1 therapies and help you explore whether these medications could be right for you.
- Talk to us today about your options for diabetes and weight management, and stay proactive about your health.
- Visit us in-store or book a consultation online.
Centrum Pharmacy — Where Your Health Comes First.
Disclaimer: The medical information on this site is provided as an information resource only and is not to be used or relied on for any diagnostic or treatment purposes. This information does not substitute for professional diagnosis and treatment. Please do not initiate, modify, or discontinue any treatment, medication, or supplement solely based on this information. Always seek the advice of your healthcare provider first. Full Disclaimer.
